HYFT Share Price Performance
US$1.79
1.36 (316.28%)
40.3% undervalued intrinsic discount
US$3.00
Fair Value
Price US$1.79
AnalystLowTarget US$3.00
AnalystHighTarget US$5.00
AnalystConsensusTarget US$4.00
Fair ValueUS$3.00
Share Pricen/a
MindWalk Holdings Corp. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
HYFT Community Narratives
AN
Fair Value US$3 40.3% undervalued intrinsic discount
Margin Pressures Will Intensify Yet AI Progress Will Stabilize
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$5 64.2% undervalued intrinsic discount
AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery
0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
Fair Value US$4 55.3% undervalued intrinsic discount
AI-Driven Discovery Will Advance Biologic Drug Development
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery
Key Takeaways AI-powered platforms and regulatory tailwinds uniquely position the company for outsized margin expansion, industry leadership, and sustained revenue surprises beyond analyst expectations. Streamlined operations and a focused, platform-driven strategy will accelerate service adoption, high-value contract wins, and recurring revenue growth in biologic drug development.Read more
32
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AN
US$5
64.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
23.12% p.a.
Profit Margin
18.72%
Future PE
55.89x
Price in 2028
US$3.41
Margin Pressures Will Intensify Yet AI Progress Will Stabilize
Key Takeaways Increasing adoption of AI-driven platforms and regulatory shifts boost growth prospects, but competition, compliance complexity, and sector consolidation could pressure margins and pricing. Operational improvements and platform differentiation support earnings, yet macroeconomic risks and service commoditization may limit margin expansion and recurring growth.Read more
13
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$3
40.3% undervalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
23.1% p.a.
Profit Margin
18.7%
Future PE
33.51x
Price in 2028
US$2.05
AI-Driven Discovery Will Advance Biologic Drug Development
Key Takeaways Accelerated adoption of AI-driven platforms and regulatory changes are boosting demand for ImmunoPrecise's scalable, high-margin discovery and screening services. Strategic partnerships, operational efficiencies, and core market expansion are supporting recurring revenue growth, improved margins, and stronger long-term earnings stability.Read more
209
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
US$4
55.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
21.16% p.a.
Profit Margin
16.63%
Future PE
52.75x
Price in 2028
US$2.73
Trending Discussion
Recently Updated Narratives
AN
Margin Pressures Will Intensify Yet AI Progress Will Stabilize
Fair Value: US$3 40.3% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI Platforms Will Revolutionize Personalized Biologics And Computational Discovery
Fair Value: US$5 64.2% undervalued intrinsic discount
4 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AI-Driven Discovery Will Advance Biologic Drug Development
Fair Value: US$4 55.3% undervalued intrinsic discount
17 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
MindWalk Holdings Corp. Key Details
About HYFT
- Founded
- 1983
- Employees
- 92
- CEO
- WebsiteView website
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed its name to MindWalk Holdings Corp. in September 2025. The company was incorporated in 1983 and is headquartered in Austin, Texas.
